Eiger BioPharmaceuticals Reports Third Quarter 2021 Financia

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Related Keywords

France , Brazil , Erik Atkisson , Progeroid Laminopathies , David Cory , Company Annual Report On Form , Eiger Biopharmaceuticals Inc , Committee For Medicinal Products Human Use , Program Updates , Nasdaq , Eiger Biopharmaceuticals , Hepatitis Delta Virus , Peginterferon Lambda , Rare Metabolic , Processing Deficient Progeroid , Medicinal Products , Human Use , Temporary Use Authorization , Erik Atkisson General Counsel , Chief Compliance Officer , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial , Nc ,